Regeneron Shares Drop After Late-Stage Trial Failure for Skin Cancer Treatment
Regeneron's shares fell by 12% following the failure of its experimental skin cancer treatment in a late-stage trial. The combination therapy, fianlimab and cemiplimab, did not achieve statistical significance in improving progression-free survival compared to Merck’s Keytruda.